MARKET

AVTX

AVTX

Avalo Therapeutics Inc
NASDAQ
14.19
+1.04
+7.91%
After Hours: 14.19 0 0.00% 16:10 02/06 EST
OPEN
13.50
PREV CLOSE
13.15
HIGH
14.45
LOW
13.19
VOLUME
319.37K
TURNOVER
--
52 WEEK HIGH
20.72
52 WEEK LOW
3.390
MARKET CAP
257.32M
P/E (TTM)
-1.6140
1D
5D
1M
3M
1Y
5Y
1D
Piper Sandler Keeps Their Buy Rating on Avalo Therapeutics (AVTX)
TipRanks · 3d ago
Avalo Therapeutics nimmt an Investorenkonferenzen teil
Reuters · 3d ago
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case
Benzinga · 5d ago
This Avalo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Benzinga · 5d ago
Avalo Therapeutics Price Target Announced at $50.00/Share by Guggenheim
Dow Jones · 5d ago
Guggenheim Initiates Coverage On Avalo Therapeutics with Buy Rating, Announces Price Target of $50
Benzinga · 5d ago
Guggenheim starts Avalo at Buy on hidradenitis suppurativa potential
TipRanks · 5d ago
Avalo Therapeutics initiated with a Buy at Guggenheim
TipRanks · 5d ago
More
About AVTX
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.

Webull offers Avalo Therapeutics Inc stock information, including NASDAQ: AVTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVTX stock methods without spending real money on the virtual paper trading platform.